HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

BackgroundUnderstanding carboplatin resistance in ovarian cancer is critical for the improvement of patients’ lives. Multipotent mesenchymal stem cells or an aggravated epithelial to mesenchymal transition phenotype of a cancer are integrally involved in pathways conferring chemo-resistance. Long non-coding RNA HOTAIR (HOX transcript antisense intergenic RNA) is involved in mesenchymal stem cell fate and cancer biology.MethodsWe analyzed HOTAIR expression and associated surrogate DNA methylation (DNAme) in 134 primary ovarian cancer cases (63 received carboplatin, 55 received cisplatin and 16 no chemotherapy). We validated our findings by HOTAIR expression and DNAme analysis in a multicentre setting of five additional sets, encompassing 946 ovarian cancers. Chemo-sensitivity has been assessed in cell culture experiments.ResultsHOTAIR expression was significantly associated with poor survival in carboplatin-treated patients with adjusted hazard ratios for death of 3.64 (95 % confidence interval [CI] 1.78–7.42; P < 0.001) in the discovery and 1.63 (95 % CI 1.04–2.56; P = 0.032) in the validation set. This effect was not seen in patients who did not receive carboplatin (0.97 [95 % CI 0.52–1.80; P = 0.932]). HOTAIR expression or its surrogate DNAme signature predicted poor outcome in all additional sets of carboplatin-treated ovarian cancer patients while HOTAIR expressors responded preferentially to cisplatin (multivariate interaction P = 0.008).ConclusionsNon-coding RNA HOTAIR or its more stable DNAme surrogate may indicate the presence of a subset of cells which confer resistance to carboplatin and can serve as (1) a marker to personalise treatment and (2) a novel target to overcome carboplatin resistance.

[1]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[2]  Howard Y. Chang,et al.  Molecular mechanisms of long noncoding RNAs. , 2011, Molecular cell.

[3]  H. Steed,et al.  Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. , 2013, Gynecologic oncology.

[4]  R. Medema,et al.  Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. , 2011, Cancer cell.

[5]  Chiara Romualdi,et al.  Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. , 2013, European journal of cancer.

[6]  Howard Y. Chang,et al.  Long intergenic noncoding RNAs: new links in cancer progression. , 2011, Cancer research.

[7]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[8]  M. Widschwendter,et al.  MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status , 2003, British Journal of Cancer.

[9]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[10]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[11]  Andrew E. Teschendorff,et al.  Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies , 2011, Bioinform..

[12]  P. Disaia,et al.  A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Markman.  Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. , 2008, Trends in pharmacological sciences.

[14]  H. Hollema,et al.  Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.

[15]  Li-tao Yang,et al.  Knockdown of Long Non-coding RNA HOTAIR Suppresses Tumor Invasion and Reverses Epithelial-mesenchymal Transition in Gastric Cancer , 2013, International journal of biological sciences.

[16]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[17]  M. Andreeff,et al.  Origins of the Tumor Microenvironment: Quantitative Assessment of Adipose-Derived and Bone Marrow–Derived Stroma , 2012, PloS one.

[18]  M. Buyse,et al.  ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer , 1998, The Lancet.

[19]  J. Arseneau,et al.  A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study) , 2004, Investigational New Drugs.

[20]  J. Malek,et al.  Mesenchymal Cell Interaction with Ovarian Cancer Cells Triggers Pro-Metastatic Properties , 2012, PloS one.

[21]  A. Teschendorff,et al.  An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer , 2009, PloS one.

[22]  D. Alberts,et al.  A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. , 1990, Gynecologic oncology.

[23]  Kathleen R. Cho,et al.  Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. , 2011, The Journal of clinical investigation.

[24]  T. Brümmendorf,et al.  Pluripotent stem cells escape from senescence-associated DNA methylation changes , 2013, Genome research.

[25]  W. Yuan,et al.  HOTAIR enhanced aggressive biological behaviors and induced radio-resistance via inhibiting p21 in cervical cancer , 2015, Tumor Biology.

[26]  M. Gore,et al.  Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. , 2007, Critical reviews in oncology/hematology.

[27]  Matheus C. Bürger,et al.  Brief Report: The lincRNA Hotair Is Required for Epithelial‐to‐Mesenchymal Transition and Stemness Maintenance of Cancer Cell Lines , 2013, Stem cells.

[28]  K. Hua,et al.  The long non-coding RNA HOTAIR promotes the proliferation of serous ovarian cancer cells through the regulation of cell cycle arrest and apoptosis. , 2015, Experimental cell research.

[29]  M. Widschwendter,et al.  Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. , 2000, Journal of the National Cancer Institute.

[30]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[31]  Wolfgang Wagner,et al.  Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. , 2010, Genome research.

[32]  E. Berns,et al.  Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) , 2010, British journal of pharmacology.

[33]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[34]  K. Hua,et al.  Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. , 2014, Gynecologic oncology.

[35]  E. Berns,et al.  Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. , 2010, Gynecologic oncology.

[36]  Yu-qin Pan,et al.  Prognostic Value of Long Non-Coding RNA HOTAIR in Various Cancers , 2014, PloS one.

[37]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.